PMID- 33108530
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20210629
IS  - 1434-9949 (Electronic)
IS  - 0770-3198 (Print)
IS  - 0770-3198 (Linking)
VI  - 40
IP  - 6
DP  - 2021 Jun
TI  - One-year efficacy and safety of single or one to three weekly injections of hylan 
      G-F 20 for knee osteoarthritis: a systematic literature review and meta-analysis.
PG  - 2133-2142
LID - 10.1007/s10067-020-05477-7 [doi]
AB  - The aim of this study was to evaluate the long-term efficacy and safety of single 
      or 1-3 weekly injections of hylan G-F 20 at 1 year following the first injection 
      for knee osteoarthritis (OA). Searches were conducted in PubMed/MEDLINE, Embase, 
      and CENTRAL and included relevant conference proceedings (January 1, 1995-August 
      17, 2020). Randomized controlled trials (RCTs), non-randomized trials, and 
      observational studies investigating 1-year efficacy and safety of 1-3 weekly 
      injections or single hylan G-F 20 injection for knee OA were included. Primary 
      outcomes were WOMAC pain, physical function, and stiffness. Meta-analyses of RCTs 
      and non-randomized studies were conducted separately. Our search identified 24 
      eligible studies. Hylan G-F 20, in the meta-analyses of RCTs, showed 
      statistically significant improvement in WOMAC pain (SMCC - 0.98, 95% CI - 1.50, 
      - 0.46), physical function (SMCC - 1.05, 95% CI - 1.28, - 0.83), and stiffness 
      (SMCC - 1.07, 95% CI -1.28, -0.86). Improvement was also seen for VAS pain, SF-36 
      MCS (mental component summary), and SF-36 PCS (physical component summary). 
      Analyses of non-randomized studies showed similar efficacy estimates. There were 
      no significant differences in efficacy based on injection schedule, nor between 
      RCT and non-randomized studies. Rates of adverse events (AEs) were low for most 
      types of AEs. Hylan G-F 20 (either as single or 1-3 weekly injections) showed 
      improvement in 1-year efficacy outcomes in comparison to baseline and was 
      generally well tolerated. While further research will inform the medical field 
      regarding viscosupplementation treatment options for knee OA, these findings show 
      that hylan G-F 20 at both frequencies/dosages are efficacious and generally well 
      tolerated for long-term use.
FAU - De Lucia, Orazio
AU  - De Lucia O
AD  - Clinical Rheumatology Unit, Department of Rheumatology and Medical Sciences, ASST 
      Centro Traumatologico Ortopedico G. Pini-CTO, Milan, Italy.
FAU - Jerosch, Joerg
AU  - Jerosch J
AD  - Orthopedic Department, Johanna Etienne Hospital, Am Hasenberg 46, 41462, Neuss, 
      Germany.
FAU - Yoon, Sophie
AU  - Yoon S
AD  - Doctor Evidence, Santa Monica, CA, USA.
FAU - Sayre, Tobias
AU  - Sayre T
AD  - Doctor Evidence, Santa Monica, CA, USA.
FAU - Ngai, Wilson
AU  - Ngai W
AD  - Global Medical Affairs, Sanofi, Bridgewater, NJ, USA.
FAU - Filippou, Georgios
AU  - Filippou G
AUID- ORCID: 0000-0002-1647-2083
AD  - ASST Fatebenefratelli, University Hospital "Luigi Sacco", Rheumatology Unit, Via 
      Giovanni Battista Grassi, 74, 20157, Milan, Italy. gf.filippou@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20201027
PL  - Germany
TA  - Clin Rheumatol
JT  - Clinical rheumatology
JID - 8211469
RN  - 125935-84-4 (hylan)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Humans
MH  - Hyaluronic Acid/adverse effects/analogs & derivatives
MH  - Injections, Intra-Articular
MH  - *Osteoarthritis, Knee/drug therapy
MH  - Pain
MH  - Treatment Outcome
PMC - PMC8121739
OTO - NOTNLM
OT  - Hylan G-F 20
OT  - Injections
OT  - Knee
OT  - Osteoarthritis
OT  - Osteoarthritis therapy
COIS- Orazio De Lucia has no conflicts of interest to declare. Joerg Jerosch has served 
      on advisory boards for Sanofi. Sophie Yoon and Tobias Sayre are employed by 
      Doctor Evidence LLC, which was contracted by Sanofi to conduct the analysis. 
      Wilson Ngai is currently employed by Sanofi. Georgios Filippou has no conflicts 
      of interest to declare.
EDAT- 2020/10/28 06:00
MHDA- 2021/05/19 06:00
PMCR- 2020/10/27
CRDT- 2020/10/27 17:38
PHST- 2020/07/15 00:00 [received]
PHST- 2020/10/22 00:00 [accepted]
PHST- 2020/10/21 00:00 [revised]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2020/10/27 17:38 [entrez]
PHST- 2020/10/27 00:00 [pmc-release]
AID - 10.1007/s10067-020-05477-7 [pii]
AID - 5477 [pii]
AID - 10.1007/s10067-020-05477-7 [doi]
PST - ppublish
SO  - Clin Rheumatol. 2021 Jun;40(6):2133-2142. doi: 10.1007/s10067-020-05477-7. Epub 
      2020 Oct 27.